<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="366364">
  <stage>Registered</stage>
  <submitdate>18/05/2014</submitdate>
  <approvaldate>2/06/2014</approvaldate>
  <actrnumber>ACTRN12614000586617</actrnumber>
  <trial_identification>
    <studytitle>Can nitric oxide donors treatment improve pregnancy outcome in patients with antiphospholipid syndrome?   </studytitle>
    <scientifictitle>Prospective, randomized, controlled trial comparing low dose aspirin plus low molecular weight heparin and low dose aspirin plus nitric oxide donors as regards pregnancy outcome in patients with history of obstetric morbidity due to antiphospholipid syndrome.  </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Antiphospholipid syndrome</healthcondition>
    <healthcondition>recurrent abortion</healthcondition>
    <healthcondition>premature labor</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Abortion</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Prospective, randomized controlled trial. Two groups of pregnant women each 17 cases with a history of recurrent abortion or premature labor due to antiphospholipid syndrome were randomized to a control group treated once daily with oral low dose aspirin 81 mg plus subcutaneous low molecular weight heparin 40 mg, and a study group treated once daily with low dose aspirin 81 mg plus isosorbid mononitrate 20 mg tablet applied vaginally. Treatment started once pregnancy was confirmed by B-hCG and ultrasound examination and continued until the end of pregnancy. Adherence to the treatment was confirmed by the aspirin tablet and low molecular weight heparin vial return   </interventions>
    <comparator>Control group received the traditional treatment of oral low dose aspirin 81 mg plus subcutaneous low molecular weight heparin 40 mg</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of full term live birth</outcome>
      <timepoint>End of pregnancy at 37-40 weeks gestation </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Compliance of patients to treatment in both groups was assessed by drug tablet return and satisfaction with treatment in both groups was assessed using structured interviews </outcome>
      <timepoint>End of pregnancy</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of  abortion </outcome>
      <timepoint>termination of pregnancy before 20 weeks gestation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Doppler ultrasound measurement of uterine artery resistance and pulsation indices at 24 weeks after treatment compared to before treatment</outcome>
      <timepoint>At 24 weeks gestation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Patients with recurrent abortion or premature labor with preclampsia due to antiphospholipid syndrome </inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>30</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Recurrent abortion or premature labor due to causes other than antiphospholipid syndrome as uterine anomalies, cervical incompetence and chronic diseases </exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/01/2009</anticipatedstartdate>
    <actualstartdate>1/01/2009</actualstartdate>
    <anticipatedenddate>1/12/2013</anticipatedenddate>
    <actualenddate>1/12/2013</actualenddate>
    <samplesize>34</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>Kalyoupia, Benha</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Benha university hospital</primarysponsorname>
    <primarysponsoraddress>Benha, Kalyoupia, Farid Nada street</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Benha university</fundingname>
      <fundingaddress>Benha, Kalyoupia, Farid Nada street</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>Benha university hospital</sponsorname>
      <sponsoraddress>Kalyoupia, Benha, Farid Nada street</sponsoraddress>
      <sponsorcountry>Egypt</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Adverse pregnancy outcome as recurrent abortion, premature labor and severe preeclampsia  due to antiphospholipid syndrome is attributed to placental thrombosis; So, the traditional treatment is oral low dose aspirin plus subcutaneous low molecular weight heparin. Results in most studies are unsatisfactory because other pathologies do exist. Impaired synthesis of endogenous nitric oxide has been recently put forward. In this study we compare the traditional treatment with low dose aspirin plus the nitric oxide donors isosorbid mononitrate applied vaginally with the aim of improving pregnancy outcome especially the live birth rate </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Department of Obstetrics and Gynecology</ethicname>
      <ethicaddress>Benha university hospital, Farid Nada street, Benha, Kalyoupia</ethicaddress>
      <ethicapprovaldate>1/01/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>1/01/2009</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Mohamed Abdelrazik</name>
      <address>Department of Obstetrics and Gynecology, Benha university hospital, Farid Nada street, Benha , Kalyoupia</address>
      <phone>+20    02 26070837  or +2  013  3225385</phone>
      <fax />
      <email>Prof.mohamedabdelrazik@hotmail.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Mohamed Abdelrazik</name>
      <address>Department of Obstetrics and Gynecology, Benha university hospital, Farid Nada street, Benha , Kalyoupia</address>
      <phone>+20    02 26070837  or +2  013  3225385</phone>
      <fax />
      <email>Prof.mohamedabdelrazik@hotmail.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Mohamed Abdelrazik</name>
      <address>Department of Obstetrics and Gynecology, Benha university hospital, Farid Nada street, Benha , Kalyoupia</address>
      <phone>+20    02 26070837  or +2  013  3225385 </phone>
      <fax />
      <email>Prof.mohamedabdelrazik@hotmail.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>